BOLT
Bolt BiotherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.17M
P/E Ratio
—
EPS
$-16.40
Beta
1.13
52W High
$7.20
52W Low
$3.91
50-Day MA
$4.81
200-Day MA
$5.17
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.
Fundamentals
| Revenue (TTM) | $6.50M |
| Gross Profit (TTM) | $-17.43M |
| EBITDA | $-29.02M |
| Operating Margin | -29235.00% |
| Return on Equity | -88.80% |
| Return on Assets | -28.10% |
| Revenue/Share (TTM) | $3.59 |
| Book Value | $10.32 |
| Price-to-Book | 0.46 |
| Price-to-Sales (TTM) | 1.41 |
| EV/Revenue | 1.321 |
| EV/EBITDA | 0.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -97.90% |
| Shares Outstanding | $1.92M |
| Float | $1.77M |
| % Insiders | 7.11% |
| % Institutions | 28.86% |
Historical Volatility
HV 10-Day
80.01%
HV 20-Day
81.22%
HV 30-Day
73.28%
HV 60-Day
82.22%
HV Rank
51.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($41.00 target)
2
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026